Skip to content
Skip to navigation menu

 

Prof Paul Kemp  -  DPhil (Oxon)


Position:Professor

Telephone:+44(0)29 208 79347
Extension:79347
Location:Cardiff School of Biosciences, The Sir Martin Evans Building, Museum Avenue, Cardiff, CF10 3AX

General Statement of Research Activity

My complementary research interests are in the general areas of regenerative medicine and respiratory molecular physiology, and are:

  1. Human ES and iPS cell fate-determination, function and pathology, with specific emphasis on Huntington’s Disease (Patch-clamp and calcium imaging).
  2. Calcium sensing receptor in airway signal transduction and inflammatory lung diseases;.
  3. Molecular physiology of O2 sensing ion channels (K2P KCa and P2X channels);
  4. Genetically encoded sensor/transducer systems for programmed cell death in cell replacement therapies (unnatural amino acid synthetic biology).

Each research theme has been continuously and independently funded since my appointment to the post of Lecturer at The University of Leeds in October 1997. I have a high international profile in the field of control of cellular excitability, and have a particularly strong track record in the area of oxygen sensing, including a very highly cited paper in Science some 10 years ago. Recently, Prof Allen and I have been collaborating in the field of disease modeling using neurons generated from patient-derived iPS cells and were asked in 2010 to join an International Consortium aimed at unravelling the molecular basis of neuronal dyfunction in Huntington's Disease, this was renewed in 2014. Recently, we have made a particularly important breakthrough, linking HD genotype to neuronal glutamate excitotoxicity processes - these data, along with the basic cell biology of HD patient-derived iPS generated neruons - has been recently published in Cell Stem Cell (IF=26). The collaboration with Prof Riccardi has resulted in a successful patent concerning a novel treatment strategy for inflammatory lung diseases. This exciting avenue has attracted significant venture capital and big pharma attention, and capitalization is expected by 2015.

 

Research Division

Pathophysiology and Repair